drugset / Trial / NCT04666636
Mechanisms for Activation of Beige Adipose Tissue in Humans
Phase 2
Recruiting
65 enrolled
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
Timeline
- Start
- 2020-12-07
- Primary completion
- 2027-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirabegron | Other / unclassified | 25 mg | Oral |
| Subject | Mirabegron | Other / unclassified | 50 mg | Oral |
| Subject | Mirabegron | Other / unclassified | 100 mg | Oral |